Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
HAMPTON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
- Celldex is currently planning two Phase 3 studies of barzolvolimab in CSU, which are expected to initiate this summer.
- Celldex is currently planning for the initiation of a Phase 2 subcutaneous study in prurigo nodularis (PN) in early 2024.
- The litigation settlement related loss had a ($0.26) impact on net loss per share for the twelve months ended December 31, 2023.
- Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.